Scenic Biotech appoints CSO Dr. Bürli to drive the pipeline, build leadership, and move innovative biotech therapies for neurodegenerative and metabolic diseases.

Scenic Biotech has announced the hiring of Dr. Roland W. Bürli as their Chief Scientific Officer (CSO), with more than 25 years of experience in drug development and leadership from pharma and biotech companies. Dr. Bürli will lead Scenic's scientific plans and work to advance the development of new treatments aimed at neurodegenerative and metabolic diseases.

"Roland's formidable role in biotech and neighbors' experience in small molecule therapeutics add strength to our capacity to expand the pipeline quickly and drive programs towards clinical assessment," said Oscar Izeboud, CEO of Scenic Biotech. "His contributions are seminal in maximizing the potential of our modifier therapies to change patient outcomes."

Dr. Bürli said he is excited to join Scenic Biotech in its work with the innovative approach to translating modifier gene knowledge into novel therapeutics. "The recent validation of our work in high-impact publications highlights this promise of our Cell-Seq platform," he said, noting his commitment to promoting the company's pipeline.

Previously, Dr. Bürli headed up drug discovery at Codify Therapeutics and Cerevance, leading multidisciplinary teams and driving multiple preclinical and clinical-stage drug candidates. His career spans senior scientific positions in AstraZeneca, BioFocus, Amgen, and GeneSoft, contributing to the breakthroughs in CNS, inflammation, hematology, and anti-infectives. He is a co-author and inventor on more than 135 publications and patents with a doctorate from ETH Zurich and postdoctoral experience at Caltech.

Scenic Biotech's election of Dr. Bürli is a significant move in growing its leadership in the biotech sector and in advancing its mission to develop transformative therapies.